| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, Müller OA. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994;130:125–31. ISSN 0804–4643
The effect of the long-acting somatostatin analog octreotide (SMS 201-995) on adrenocorticotropin (ACTH) secretion was studied in five patients with untreated Cushing's disease in vivo and in six human corticotropic adenoma cell cultures in vitro. For the in vivo study, 100 µg of octreotide sc was given 30 and 180 min after cannulation of the cubital vein and 100 µg of corticotropin-releasing hormone (CRH) was injected iv at 210 min. Serum ACTH and cortisol levels were measured for 390 min. In vivo, octreotide had no significant effect either on basal or CRH-stimulated ACTH levels and did not influence cortisol levels. The in vitro studies were conducted with corticotropic adenoma cell cultures derived from adenoma tissue obtained from six patients with Cushing's disease. In four of six cell cultures, octreotide (1 nmol/l–1 µmol/l) inhibited basal ACTH secretion in a dose-dependent manner. The inhibition ranged from 70 to 92% for 1 nmol/l octreotide to 14–46% for 1 µmol/l octreotide as compared to controls (100%). In three of three octreotide-responsive adenoma cell cultures investigated, CRH-stimulated ACTH secretion was suppressed by octreotide. Hydrocortisone pretreatment in vitro abolished the inhibitory effect of octreotide on ACTH secretion in one octreotide-responsive corticotropic adenoma cell culture. In conclusion, we showed that octreotide in most cases could inhibit the ACTH release from human corticotropic adenoma cells in vitro but had no suppressive effect on ACTH levels of patients with Cushing's disease in vivo. This discrepancy could be due to a somatostatin receptor down-regulation by cortisol at the hypercortisolemic state in vivo.
Günter K Stalla, Max-Planck-Institute of Psychiatry, Clinical Institute, Kraepelinstr. 10, D-80804 Munich, Germany
This article has been cited by other articles:
|
|
 |
|
  C de Bruin, R A Feelders, A M Waaijers, P M van Koetsveld, D M Sprij-Mooij, S W J Lamberts, and L J Hofland Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro J. Mol. Endocrinol., January 1, 2009; 42(1): 47 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Giordano, A Picu, L Bonelli, F Broglio, F Prodam, S Grottoli, G Muccioli, E Ghigo, and E Arvat The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease Eur. J. Endocrinol., October 1, 2007; 157(4): 393 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Nolan, H. A. Schmid, and A. Levy Octreotide and the Novel Multireceptor Ligand Somatostatin Receptor Agonist Pasireotide (SOM230) Block the Adrenalectomy-Induced Increase in Mitotic Activity in Male Rat Anterior Pituitary Endocrinology, June 1, 2007; 148(6): 2821 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van der Hoek, S. W J Lamberts, and L. J Hofland Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S45 - S51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Batista, X. Zhang, R. Gejman, P. J. Ansell, Y. Zhou, S. A. Johnson, B. Swearingen, E. T. Hedley-Whyte, C. A. Stratakis, and A. Klibanski The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4482 - 4488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B Tirovola and J. S Malpas Treatment with octreotide to suppress corticotropin secretion by a carcinoid tumour J R Soc Med, November 1, 2005; 98(11): 516 - 516. [Full Text] [PDF]
|
|
|
|
 |
|
 J. van der Hoek, M. Waaijers, P. M. van Koetsveld, D. Sprij-Mooij, R. A. Feelders, H. A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J. E. Taylor, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E278 - E287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J Hofland, J. van der Hoek, R. Feelders, M. O van Aken, P. M van Koetsveld, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, W. W de Herder, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 Eur. J. Endocrinol., April 1, 2005; 152(4): 645 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J Acosta-Gomez, M A Muros, J M Llamas-Elvira, A Ramirez, S Ortega, G Sabatel, C Ramos, and A de la Riva-Aguilar The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours Br. J. Radiol., February 1, 2005; 78(926): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsagarakis, M. Christoforaki, H. Giannopoulou, F. Rondogianni, I. Housianakou, C. Malagari, D. Rontogianni, I. Bellenis, and N. Thalassinos A Reappraisal of the Utility of Somatostatin Receptor Scintigraphy in Patients with Ectopic Adrenocorticotropin Cushing's Syndrome J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4754 - 4758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Pagotto, G. Marsicano, F. Fezza, M. Theodoropoulou, Y. Grubler, J. Stalla, T. Arzberger, A. Milone, M. Losa, V. Di Marzo, et al. Normal Human Pituitary Gland and Pituitary Adenomas Express Cannabinoid Receptor Type 1 and Synthesize Endogenous Cannabinoids: First Evidence for a Direct Role of Cannabinoids on Hormone Modulation at the Human Pituitary Level J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2687 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tabarin, N. Valli, P. Chanson, Y. Bachelot, V. Rohmer, V. Bex-Bachellerie, B. Catargi, P. Roger, and F. Laurent Usefulness of Somatostatin Receptor Scintigraphy in Patients with Occult Ectopic Adrenocorticotropin Syndrome J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1193 - 1202. [Abstract] [Full Text]
|
|
|
|
 |
|
 W W DE HERDER and S W J LAMBERTS Octapeptide somatostatin-analogue therapy of Cushing's syndrome Postgrad. Med. J., February 1, 1999; 75(880): 65 - 66. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
